
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
The editors of Contemporary Pediatrics thank the esteemed professionals who serve on our Behavior: Ask the Experts panel. At the start of this new year, we share their names with you.






